Peter Kolchinsky graduated from Harvard with a Ph.D. in virology in 2001. Habib brings to RAVen nearly three decades of experience as a strategic leader in Big Pharma and emerging Biotech. Brackett has a BS in Biology with a minor in Spanish from Davidson College. Brigid was responsible for starting the venture fund and led investments in multiple sectors, including advanced analytics platforms, biomining and bioremediation, novel chemical leaching, long-duration energy storage, traceability of products, carbon removal, and green steel. Kate Moreau is an Associate Director within the TechAtlas division of RA Capital Management. Raj holds a BA from Cornell University, where he majored in Chemistry. Laura is an Executive Assistant at RA Capital Management. Prior to this role, Tom conducted research and analysis for competitive landscapes of drugs and medical devices across a range of disease indications and capabilities as a Senior Research Assistant. Adam Rosenberg is an Advisor for RA Capital Management. Michael Varnum is a Research Assistant at RA Capital Management. Alex comes to RA from Mirai Advisory, where he specialized in financial risk and data science and developed machine learning algorithms to support banks managing regulatory and operational challenges. Lorena's primary responsibility is to oversee all accounting related activities for the firm. Drinking, Drugs & Smoking Not present. Alyssa Larson is an Associate Director within the TechAtlas division at RA Capital Management. Prior to Evotec, Cony worked at IGEN, where he was responsible for the marketing strategy of the life sciences division; in addition, he was involved in investor presentations and fundraising. Monicas primary responsibilities are to drive internal and external strategic and diligence initiatives and oversee the workflow and professional development of TechAtlas Associates. He completed his residency in internal medicine at Yale-New Haven Hospital and completed his clinical gastroenterology fellowship at Massachusetts General Hospital / Harvard Medical School as well post-doctoral training with Frederick Alt, an HHMI investigator, in molecular immunology. Sri Mahendra is a Senior Software Engineer at RA Capital Management. RA Capital | Team Prior to joining Achillion, Milind was Group Leader at Bristol-Myers Squibb for all early stage discovery programs in infectious diseases and neuroscience. Shan Shan holds a PhD in Neuroscience from Harvard University and a BS in Brain and Cognitive Sciences from MIT. Most recently, David served as Director of Operations at Corbin Capital Partners, LP. Danielle received her PhD in Neuroscience from the Massachusetts Institute of Technology. Ben holds a BS in Biology and an MS in Virology from the University of Nebraska, Lincoln, and a PhD in Cancer Biology from the Tufts University School of Medicine. Lucas primary responsibilities are to advise on regulatory matters and assist in the development, implementation, and testing of the compliance program. Jeff holds a BA in Economics and Psychology from Georgetown. His prior posts include Fund Accountant at Nautic Partners and HLM Venture Partners. Prior to this, Cosmas was a Director at Takeda Pharmaceuticals where he was responsible for developing multiple partnerships and platforms on emerging technologies, along with leading drug development teams in cell and gene therapies. Jeff Breay is a Head Trader at RA Capital Management. Andrew is a Software Developer at RA Capital Management. She holds a BS in Corporate Finance & Accounting and an MBA from Salem State University. He is also active in the firms outreach efforts, speaking frequently both at industry events and in classrooms. Erich holds a BA in English Literature and Language from Harvard University and a PhD in Microbiology from the University of North Carolina, Chapel Hill. Gabe Fox is an Associate with the TechAtlas division of RA Capital Management. He previously served as the CFO of Research Alliance Corp I before its merger with Point Biopharma and served on the boards of Research Alliance Corp I and Research Alliance Corp II. Peter Kolchinsky was born in the United States of America. 1 reply 0 retweets 13 likes She previously worked as a Finance Associate at the MFA Companies. Patrick received his PhD in Natural Sciences, specifically Biochemistry and Molecular Biology, from the Leopold-Franzens University, Innsbruck, Austria. Prior to Flagship, Emily held roles as Associate Director, Head of Global Talent Acquisition and Associate Director, Recruiting Operations & Analytics at bluebird bio. Kathryn's primary responsibilities at RA Capital are to coordinate calendars, events, and company meetings for the TechAtlas division. Prior to joining the team at Enara Sophie was a medical oncologist at Guys and St Thomas NHS Foundation Trust in London, UK (GSTT). Kriti previously served as Co-Director and Regional Director, South Asia for MIT Hacking Medicine. GREENWICH Peter Crumbine, a mainstay of public service in Greenwich for decades whose level-headed, friendly and professional manner earned . He was also a Board Member of the Fannie & John Hertz Foundation and served as a judge for the Lemelson-MIT StudentPrize for Inventorship. Prior to KPMG, TJ worked within the AP/Office Admin function with the Boston Red Sox. Kats primary responsibility is supporting newcos, portfolio companies and executives within RAVen, focusing on strategic finance. Ed holds a PhD in neuroscience from the University of California Berkeley, an MS in psychology from Villanova University, and a BA from La Salle University. Adison is an Executive Assistant RA Capital Management. Ross primary responsibility at RA Capital is to create competitive landscapes of drugs and medical devices for disease indications and capabilities. Alyssa previously worked as a Senior Scientist at Eagle Pharmaceuticals. Prior to Q32 Bio, Maryann worked as the Operations Manager for Surface Oncology and several other biotech start-up companies from discovery research through end of Phase 2 Clinical trials. Peter's age is in line with some of the older Vanderpump Rules cast members, like Jax, Tom Sandoval, and Tom Schwartz. As Executive Director of Business Development at Celgene, Emily was responsible for all aspects of deal evaluation, negotiation, and execution for licensing deals, mergers and acquisitions, and collaborations, with a focus on immune-inflammatory and neurodegenerative diseases. Dan Marks is a Principal on the Venture Team at RA Capital Management. Michael received his undergraduate degree at Georgetown University and his medical degree at the Medical University of South Carolina. Sonia has a BA in Chemistry and a PhD in Bioengineering, both from the University of Pennsylvania. Danielle Feldman is the Director of Corporate Development at Aliada Therapeutics. Michael holds a BS in Exercise Science from Brigham Young University and an MD from the University of Texas Southwestern School of Medicine. Prior to joining Aberdeen, Eric worked as a Compliance Examiner at the US Securities and Exchange Commission. While at Tamarack, he managed coverage expansion into commercial-stage biotech, pharma, and specialty pharma sectors. Garrett received a BS with honors from the California Institute of Technology while publishing his first paper with Dr. Paul H. Patterson, holds a PhD in Immunology from Stanford University, where he studied hematopoietic stem and progenitor cells with Dr. Irving L. Weissman, and completed his post-doctoral training at Childrens Hospital Boston/Harvard Medical School studying ES/iPSC specification to the hematopoietic fate with Dr. George Q. Daley. Prior to joining RA Capital and Arcuate Therapeutics, Tim was President and CEO of Proteon Therapeutics, a company focused on developing novel therapeutics to improve the lives of patients with kidney and vascular diseases. Prior to RA, Rob spent 21 years at the Broad Institute of MIT and Harvard, most recently as the Senior Director of Technology Development and a Principal Investigator. Prior to RA, Drew gained experience in Data Science in Technical Consultant roles at ExxonMobil. Le Ho is a Business Systems Analyst at RA Capital Management. Any hedge fund managing over $100M is required to submit a 13F form to the SEC which lists their current holdings at the end of each fiscal quarter. Kevin has a ME in Chemistry and Chemical Engineering from Chimie ParisTech in France, a MS in Biotechnology from the Royal Institute of Technology in Sweden, and a PhD in Physics and Chemistry from Paris Sciences et Lettres Research University in France. Rez Halse is President of RAVen, also known as RA Ventures, RA Capitals company creation incubator. According to Famous Birthdays, Peter was born on June 14, 1984, which makes him 38 years old, going on 39 in 2023. From time to time we may post specific open positions, but more often we will create positions for the right people. Mario held a Project Director position at BARDA working on Universal Flu Vaccine and leading the technical selection and completion of multiyear/multi million vaccine development programs. He has over 20 academic publications, inventorship on numerous patents, and serves as reviewer for multiple journals and NIH grants committee. As the Chief Scientific Officer at Mustang Bio, Sadik managed the foundational build-out of the companys preclinical and manufacturing activities. Michael Gillespie is an Analyst on the Venture Team at RA Capital Management. He most recently served as Chief Medical Officer for Rodin Therapeutics, where he led all clinical development activities from first-in-human through patient studies until the acquisition by Alkermes. Prior to Bernstein, Joey held a Consultant role at FactSet. Sarah Reed is the General Counsel at RA Capital Management. Vikram studied engineering at the Indian Institute of Technology, Delhi before earning a BS in Operations Research with honors from Columbia University. Tyler Kowalski is an InteractiveDesigner at RA Capital Management. Prior to MP, she was a Consultant at Clarion Healthcare. Meredith is a Senior Research Assistant at RA Capital Management. Joes primary responsibility at RA is to provide technical assistance and support for issues related to computer systems, the network, and server environments. David holds a BS in Economics with a minor in Business Administration from University of Colorado Boulder. Peter Kolchinsky is a founder and managing partner at RA Capital Management and author of "The Great American Drug Deal" (Evelexa Press, 2020). Prior to these companies, James held senior research leadership roles in the gene and stem cell therapy companies Cell Genesys, Phylogix, and Somatix Therapy. in Life Science from National Taiwan University, M.S. Gabe has a BS in Biology from Cornell University and a PhD in Biology from Northeastern University. He is co-founder and CEO of Clear Creek Bio, an RA Capital portfolio company. Matthew Hammond is a Principal on the Investment Team at RA Capital Management. PETER KOLCHINSKY, PhD Managing Partner RAJEEV SHAH Managing Partner ANDREW LEVIN, MD/PhD Partner and Managing Director JOSH RESNICK, MD Senior Managing Director PETER BALOGH Analyst GUNES BOZKURT, PhD Analyst TESS CAMERON Principal NATE DAVIS Analyst DEREK DiROCCO, PhD Partner CRISTINA GHENOIU, PhD Principal MICHAEL GILLESPIE, MD Analyst Prior to this role, Kate worked with the Venture team evaluating early stage investment opportunities and mapped a number of competitive landscapes, including ophthalmology, lower GI, and non-viral liver disease.
A Patient's Urinalysis Reveals The Presence Of Glucose,
Sda Promotional Talk About Thanksgiving,
Chris Bequette Debi Thomas,
Old Whitey Kamloops Bodies,
Articles P